{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:29:15Z","timestamp":1791120555364,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.4065\/81.5.693","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"693-703","source":"Crossref","is-referenced-by-count":156,"title":["Monoclonal Gammopathy of Undetermined Significance, Waldenstr\u00f6m Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment"],"prefix":"10.4065","volume":"81","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/81.5.693_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.5.693_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/81.5.693_bib3","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosisin monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstr\u00f6m's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstr\u00f6m's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.4065\/81.5.693_bib6","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1200\/JCO.2005.06.147","article-title":"Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstr\u00f6m's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system","volume":"23","author":"Baldini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.4065\/81.5.693_bib8","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib9","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos","year":"2000","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib10","series-title":"Cecil Textbook of Medicine","first-page":"1184","article-title":"Plasma cell disorders","author":"Kyle","year":"2004"},{"key":"10.4065\/81.5.693_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/asheducation-2005.1.360","article-title":"POEMS syndrome","author":"Dispenzieri","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.4065\/81.5.693_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management","author":"Rajkumar","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.4065\/81.5.693_bib13","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","article-title":"Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later","volume":"79","author":"Kyle","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.5.693_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0025-6196(12)60015-9","article-title":"\u201cBenign\u201d monoclonal gammopathy\u2014after 20 to 35 years of follow-up","volume":"68","author":"Kyle","year":"1993","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.5.693_bib18","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V86.10.3915.bloodjournal86103915","article-title":"Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance","volume":"86","author":"Drach","year":"1995","journal-title":"Blood"},{"issue":"10, suppl 1","key":"10.4065\/81.5.693_bib19","first-page":"663a","article-title":"Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes [abstract]","volume":"94","author":"Fonseca","year":"1999","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib20","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.4065\/81.5.693_bib21","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.leu.2403555","article-title":"Genetic heterogeneity in multiple myeloma","volume":"19","author":"Magrangeas","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib24","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/sj.leu.2403970","article-title":"Growth factors and antiapoptotic signaling pathways in multiple myeloma","volume":"19","author":"van de Donk","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.leu.2403647","article-title":"Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment","volume":"19","author":"P\u00e9rez-Andr\u00e9s","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib26","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V96.12.3880","article-title":"The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells","volume":"96","author":"Rawstron","year":"2000","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/sj.leu.2403823","article-title":"CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations","volume":"19","author":"Kumar","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib28","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib29","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","article-title":"Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance","volume":"23","author":"Kumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib30","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma [published correction appears in N Engl J Med. 2005;352:1163]","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib31","first-page":"717","article-title":"Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)","volume":"89","author":"Barosi","year":"2004","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.4065\/81.5.693_bib32","first-page":"S31","article-title":"Risk factors for early progression of asymptomatic multiple myeloma [abstract]","volume":"4","author":"Weber","year":"2003","journal-title":"Hematol J"},{"issue":"11, pt 1","key":"10.4065\/81.5.693_bib33","first-page":"687a","article-title":"Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma [abstract]","volume":"102","author":"Wang","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib34","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.leu.2403857","article-title":"Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma","volume":"19","author":"Ross","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma","volume":"87","author":"Witzig","year":"1994","journal-title":"Br J Haematol"},{"key":"10.4065\/81.5.693_bib37","doi-asserted-by":"crossref","first-page":"949a","DOI":"10.1182\/blood.V106.11.3396.3396","article-title":"The natural history of smoldering (asymptomatic) multiple myeloma [abstract]","volume":"106","author":"Kyle","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.4065\/81.5.693_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A prognostic index for multiple myeloma","volume":"73","author":"Grignani","year":"1996","journal-title":"Br J Cancer"},{"key":"10.4065\/81.5.693_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.4065\/81.5.693_bib41","first-page":"604a","article-title":"Thalidomide alone or with dexamethasone for multiple myeloma [abstract]","volume":"94","author":"Weber","year":"1999","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.leu.2403905","article-title":"Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside","volume":"19","author":"Bruno","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.beha.2005.01.010","article-title":"Novel biological therapies for the treatment of multiple myeloma","volume":"18","author":"Richardson","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.4065\/81.5.693_bib44","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.leu.2403776","article-title":"Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs","volume":"19","author":"Kumar","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11864-004-0015-5","article-title":"Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Ghobrial","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.4065\/81.5.693_bib46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(03)01246-4","article-title":"Waldenstr\u00f6m macroglobulinaemia","volume":"4","author":"Ghobrial","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.4065\/81.5.693_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1634\/theoncologist.5-1-63","article-title":"Waldenstr\u00f6m's macroglobulinemia","volume":"5","author":"Gertz","year":"2000","journal-title":"Oncologist"},{"key":"10.4065\/81.5.693_bib48","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","article-title":"Study of prognosis in Waldenstr\u00f6m's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility","volume":"83","author":"Gobbi","year":"1994","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib49","first-page":"852","article-title":"Prognostic factors in Waldenstr\u00f6m macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients","volume":"96","author":"Morel","year":"2000","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-02-0833","article-title":"Update on treatment recommendations from the Third International Workshop on Waldenstr\u00f6m's Macroglobulinemia","author":"Treon","year":"2006","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib51","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2005.03.144","article-title":"Diagnosis and management of Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib52","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1080\/10428190410001723287","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with rituximab: prognostic factors for response and progression","volume":"45","author":"Dimopoulos","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.5.693_bib53","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/10428190410001714043","article-title":"Multicenter phase 2 trial of rituximab for Waldenstr\u00f6m macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)","volume":"45","author":"Gertz","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.5.693_bib54","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in Fc\u03b3RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib55","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstr\u00f6m macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"key":"10.4065\/81.5.693_bib56","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstr\u00f6m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2001","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib58","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstr\u00f6m's macroglobulinemia with 2-chlorodeoxyadenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1998.01069.x","article-title":"Bolus administration of cladribine in the treatment of Waldenstr\u00f6m macroglobulinaemia","volume":"103","author":"Liu","year":"1998","journal-title":"Br J Haematol"},{"key":"10.4065\/81.5.693_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1999.tb01848.x","article-title":"Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstr\u00f6m's macroglobulinemia","volume":"63","author":"Hellmann","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.4065\/81.5.693_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002770050247","article-title":"First-line treatment of Waldenstr\u00f6m's disease with cladribine","volume":"74","author":"Fridrik","year":"1997","journal-title":"Ann Hematol"},{"key":"10.4065\/81.5.693_bib62","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.leu.2403885","article-title":"Fludarabine plus cyclophosphamide in Waldenstr\u00f6m's macroglobulinemia: results in 49 patients","volume":"19","author":"Tamburini","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.5.693_bib63","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib64","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1703580","article-title":"Stem cell transplantation (SCT) for Waldenstr\u00f6m's macroglobulinemia (WM)","volume":"29","author":"Anagnostopoulos","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.5.693_bib65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/10428199509107907","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with very low doses of alpha interferon","volume":"19","author":"Legouffe","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.5.693_bib66","first-page":"313","article-title":"Treatment of Waldenstr\u00f6m's macroglobulinemia with interferon","volume":"74","author":"De Rosa","year":"1989","journal-title":"Haematologica"},{"key":"10.4065\/81.5.693_bib67","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/sonc.2003.50065","article-title":"Novel biologically based therapies for Waldenstr\u00f6m's macroglobulinemia","volume":"30","author":"Mitsiades","year":"2003","journal-title":"Semin Oncol"},{"key":"10.4065\/81.5.693_bib69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.beha.2005.01.030","article-title":"Amyloidosis","volume":"18","author":"Gertz","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.4065\/81.5.693_bib70","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib71","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib72","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2004-04-1424","article-title":"Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis","volume":"105","author":"Abraham","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib73","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","article-title":"Analysis of V\u03bb-J\u03bb expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (\u03bbIII) as a new amyloid-associated germline gene segment","volume":"100","author":"Perfetti","year":"2002","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib74","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib75","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1365-2141.1999.01591.x","article-title":"Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation","volume":"106","author":"Comenzo","year":"1999","journal-title":"Br J Haematol"},{"key":"10.4065\/81.5.693_bib76","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","article-title":"Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival","volume":"19","author":"Dispenzieri","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib77","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.4065\/81.5.693_bib78","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.4065\/81.5.693_bib79","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib80","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.4065\/81.5.693_bib82","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"10.4065\/81.5.693_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0268-960X(03)00027-4","article-title":"Therapy for immunoglobulin light chain amyloidosis: the new and the old","volume":"18","author":"Gertz","year":"2004","journal-title":"Blood Rev"},{"key":"10.4065\/81.5.693_bib84","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib85","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib86","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","article-title":"Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation","volume":"104","author":"Seldin","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib87","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bmt.1704539","article-title":"A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study","volume":"34","author":"Gertz","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.5.693_bib89","doi-asserted-by":"crossref","first-page":"421a","DOI":"10.1182\/blood.V106.11.421.421","article-title":"Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup) [abstract]","volume":"106","author":"Jaccard","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1704346","article-title":"High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial","volume":"33","author":"Sanchorawala","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.5.693_bib91","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2005-03-1206","article-title":"Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients","volume":"106","author":"Leung","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib92","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1600-6143.2005.00920.x","article-title":"Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement","volume":"5","author":"Leung","year":"2005","journal-title":"Am J Transplant"},{"key":"10.4065\/81.5.693_bib93","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2005-08-3253","article-title":"Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis","volume":"107","author":"Gillmore","year":"2006","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib94","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"key":"10.4065\/81.5.693_bib96","doi-asserted-by":"crossref","first-page":"252a","DOI":"10.1182\/blood.V106.11.252.252","article-title":"Lenalidomide has activity in a phase II trial in patients with primary systemic amyloidosis [abstract]","volume":"106","author":"Dispenzieri","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib97","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0889-8588(05)70124-6","article-title":"Solitary plasmacytoma of bone and extramedullary plasmacytoma","volume":"13","author":"Dimopoulos","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.4065\/81.5.693_bib98","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2002-08-2441","article-title":"Prognostic value of angiogenesis in solitary bone plasmacytoma","volume":"101","author":"Kumar","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib99","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.1993.11.7.1311","article-title":"Magnetic resonance imaging in the staging of solitary plasmacytoma of bone","volume":"11","author":"Moulopoulos","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.1992.10.4.587","article-title":"Curability of solitary bone plasmacytoma","volume":"10","author":"Dimopoulos","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.5.693_bib101","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.10366","article-title":"Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"key":"10.4065\/81.5.693_bib102","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4","article-title":"Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome","volume":"21","author":"Watanabe","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.4065\/81.5.693_bib103","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.V87.4.1458.bloodjournal8741458","article-title":"Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome","volume":"87","author":"Gherardi","year":"1996","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib104","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.5.693_bib105","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/ndt\/14.10.2370","article-title":"A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome","volume":"14","author":"Nakamoto","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.4065\/81.5.693_bib106","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0272-6386(99)70386-0","article-title":"Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome","volume":"34","author":"Soubrier","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.4065\/81.5.693_bib107","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1182\/blood-2004-05-2046","article-title":"Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611617151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611617151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:19:24Z","timestamp":1589505564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611617151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0025619611617151"],"URL":"https:\/\/doi.org\/10.4065\/81.5.693","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}